Emerging therapeutic strategies for obesity management for cardiovascular risk reduction in resource-limited settings: A review focusing on semaglutide

Authors

  • Habibie Arifianto Department of Cardiology and Vascular Medicine, Universitas Sebelas Maret, Surakarta, Indonesia; Department of Cardiology and Vascular Medicine, UNS Hospital, Solo, Indonesia
  • Antonia A. Lukito Department of Cardiology and Vascular Medicine, Universitas Pelita Harapan, Tangerang, Indonesia https://orcid.org/0000-0001-8519-8949
  • Anwar Santoso Department of Cardiology and Vascular Medicine, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia https://orcid.org/0000-0001-8247-4151
  • Ade M. Ambari Department of Cardiology and Vascular Medicine, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
  • Yudi H. Octaviono Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
  • Erwinanto Erwinanto Department of Cardiology and Vascular Medicine, Universitas Padjajaran, Bandung, Indonesia
  • Badai B. Tiksnadi Department of Cardiology and Vascular Medicine, Universitas Padjajaran, Bandung, Indonesia; Department of Cardiology and Vascular Medicine, Hasan Sadikin Hospital, Bandung, Indonesia https://orcid.org/0000-0002-0314-5577
  • Siska S. Danny Department of Cardiology and Vascular Medicine, National Cardiovascular Center Harapan Kita, Jakarta, Indonesia; Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia
  • Jordan Bakhriansyah Medical Faculty, Universitas Surabaya, Surabaya, Indonesia; National Hospital Surabaya, Surabaya, Indonesia
  • Haryadi Haryadi Eka Hospital, Pekan Baru, Indonesia

DOI:

https://doi.org/10.52225/narrax.v4i3.381

Keywords:

Obesity, cardiovascular disease, GLP-1 receptor agonist, semaglutide, resource-limited settings

Abstract

Obesity represents a major contributor to cardiovascular disease burden, particularly in resource-limited settings where prevention, early detection, and long-term management remain challenging. Excess adiposity promotes cardiometabolic dysfunction through interconnected pathways involving insulin resistance, chronic low-grade inflammation, dyslipidemia, neurohormonal activation, and adverse cardiac remodeling, ultimately increasing the risk of heart failure, ischemic heart disease, stroke, and major adverse cardiovascular events. Among emerging therapeutic targets, incretin-based pathways have gained particular attention because they address both weight reduction and cardiovascular risk modification. Semaglutide, a glucagon-like peptide-1 receptor agonist, has become one of the most clinically relevant agents in this field, with evidence showing substantial reductions in body weight and improvements in glycemic control, visceral adiposity, systemic inflammation, blood pressure, and cardiometabolic risk markers. Data further support the potential role of semaglutide in reducing cardiovascular events, including among individuals with obesity and established cardiovascular disease without type 2 diabetes. The aim of the review is to synthesize current mechanistic and clinical evidence on semaglutide as an emerging therapeutic strategy in obesity management for cardiovascular risk reduction, while briefly contextualizing its role among other novel anti-obesity pharmacotherapies. Particular attention is also given to the relevance of semaglutide in resource-limited settings. Understanding organ-specific mechanisms and prioritizing scalable interventions may support more effective cardiovascular disease risk reduction strategies in obesity within resource-constrained healthcare systems.

Downloads

Download data is not yet available.

Downloads

Published

2026-11-16

How to Cite

Arifianto, H., Lukito, A. A., Santoso, A., Ambari, A. M., Octaviono, Y. H., Erwinanto, E., … Haryadi, H. (2026). Emerging therapeutic strategies for obesity management for cardiovascular risk reduction in resource-limited settings: A review focusing on semaglutide. Narra X, 4(3), e381. https://doi.org/10.52225/narrax.v4i3.381